BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of body protection compound, a peptide first identified in human gastric juice. AminoOptimization Group supplies it in two research formats: a lyophilised powder, available in 5 mg and 10 mg vials for reconstitution into aqueous solution, and a 500 mcg oral capsule format supplied ready for use without reconstitution. Both formats are manufactured to the same 99% HPLC purity specification, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is BPC-157?
BPC-157 is a chain of 15 amino acids — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — identified as a partial sequence within body protection compound, a larger peptide originally isolated from human gastric juice. Four of the fifteen residues are proline, three of them consecutive at positions three through five. Structural work attributes much of the sequence’s resistance to proteolytic cleavage to this proline density, since proline’s cyclic side chain limits access for common gastrointestinal and serum peptidases.
This resistance to degradation is also what separates BPC-157 from most peptide fragments derived from tissue extracts: published in vitro work on the parent BPC sequence reports measurable stability across an extended incubation period in simulated human gastric juice, a property attributed to its amino acid composition. Unlike GHRH- or GHRP-class analogues, BPC-157 does not act through a defined pituitary secretagogue receptor. Its molecular target has not been established with the same certainty, and published literature continues to examine candidate binding partners.
Specifications
- Compound: BPC-157
- CAS number: 137525-51-0
- Molecular formula: C62H98N16O22
- Molecular weight: 1419.5 g/mol
- Purity: 99% HPLC
- Presentation: Lyophilised powder (5 mg, 10 mg vials); oral capsule (500 mcg)
- Available sizes: 500MCG CAPSULES / 5MG / 10MG
- Physical form: White to off-white lyophilised powder (vials); solid oral capsule (500 mcg format)
- Classification: Research peptide — not for human or veterinary use
Research context
Published research on BPC-157 concentrates on gastrointestinal and musculoskeletal tissue models. In vitro work examines the compound’s effect on fibroblast migration rates in cell culture, and rodent studies have investigated markers of angiogenesis, including VEGFR2 receptor expression and downstream signalling, in models of induced tissue injury.
A separate body of literature investigates BPC-157’s interaction with the nitric oxide system, examining nitric oxide synthase expression and NO-pathway activity in isolated tissue and animal models. The compound also appears in rodent study designs involving models of induced colitis and gastric mucosal injury, where gastrointestinal tissue markers are used as endpoints to examine proposed mechanisms of action.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Reconstitution applies only to the 5 mg and 10 mg lyophilised vial presentations. The 500 mcg capsule format is a solid oral dosage form and does not require reconstitution or any diluent.
For the lyophilised vials, bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work. Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration is a function of how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Lyophilised vials, before reconstitution: store at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state, and brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
Lyophilised vials, after reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, which are a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required. Inspect solutions before use; cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Capsules: store in the original container at room temperature, away from moisture, heat and direct light. Reconstitution and freeze-thaw stability considerations for peptide solutions do not apply to it.
Certificate of Analysis
Each lot — whether supplied as lyophilised powder or as capsules — is tested by high-performance liquid chromatography, and the 99% purity figure quoted above refers to analytical results for the specific lot supplied, not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances in the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
What distinguishes the capsule format from the lyophilised vial?
The 500 mcg capsules and the 5 mg / 10 mg lyophilised vials are manufactured to the same 99% HPLC purity specification and differ only in physical presentation. The vials require reconstitution into aqueous solution before use in a laboratory setting; the capsules are a solid oral dosage form supplied ready for use, with no reconstitution step.
Is BPC-157 approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
How much diluent should be used for the lyophilised vials?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size. This does not apply to the capsule format, which requires no diluent.
How long is reconstituted BPC-157 usable?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase, for both the vial and capsule presentations.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.